Dark Horse Consulting Group, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dark Horse Consulting Group, Inc. - overview
Established
2014
Location
Walnut Creek, CA, US
Primary Industry
Biotechnology
About
Based in Walnut Creek, US, Dark Horse Consulting Group specializes in delivering expert consulting services for the development and commercialization of cell and gene therapies. Dark Horse Consulting Group, Inc. focuses on providing consulting services to clients in the cell and gene therapy sector. Founded in 2014 by Anthony Davies, the firm has executed 2 deals as of October 2022.
The company is headquartered in Walnut Creek, California, and has expanded its presence to serve clients across North America, Europe, and select regions in Asia. Dark Horse Consulting (DHC) specializes in offering comprehensive support for cell and gene therapies (CGT). Their services encompass project management, regulatory strategy, and market analysis, assisting clients from pre-IND stages to global regulatory filings. With proprietary quantitative modeling software, DHC offers data-driven insights for academic institutions, biotechnology firms, and investors in the biopharmaceutical industry.
Dark Horse Consulting's revenue model relies on service contracts and consulting engagements with clients, primarily biotech firms and academic institutions. Revenue is generated through fixed-fee agreements, ongoing consultancy arrangements, and performance-based incentives aligned with regulatory milestones. Their core service offerings are priced based on project complexity and duration, contributing significantly to their revenue stream. In October 2022, Dark Horse Consulting Group secured an investment from WestView Capital Partners to support its growth in response to the increasing demand for expert guidance in cell and gene therapy.
The company aims to expand its offerings and geographic reach, targeting further development of its consulting services while exploring emerging markets in Asia by 2024.
Current Investors
WestView Capital Partners, Arcline Investment Management
Primary Industry
Biotechnology
Sub Industries
Consulting Services, Molecular Science, Genetics & Gene Therapy
Website
www.darkhorseconsultinggroup.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Dark Horse Consulting Group, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Bruder Consulting & Venture Group | - | ||||||||
| Add-on | Completed | Converge Consulting, LLC | - | ||||||||
| Add-on | Completed | BioTechLogic, Inc. | - | ||||||||
| Growth | Completed | Dark Horse Consulting Group, Inc. | - | ||||||||
| Growth | Completed | Dark Horse Consulting Group, Inc. | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.